Derm-Biome Pharmaceuticals adds Dr. Jerry Tan, internationally renowned expert in acne and acne scarring, to its Scientific Advisory Board
November 25, 2024 10:00 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver-based biopharmaceutical company developing safe and highly effective topical treatments...
Trent Renta Promoted to Chief Operating Officer at Olansky Dermatology & Aesthetics in Atlanta, Georgia
November 18, 2024 16:44 ET
|
Olansky Dermatology & Aesthetics
Trent Renta promoted to Chief Operating Officer
at Olansky Dermatology & Aesthetics in Atlanta, Georgia.
MJH Life Sciences® acquires Revolutionizing Atopic Dermatitis (RAD) Annual Meeting, expands leadership in dermatology education
November 18, 2024 11:00 ET
|
MJH Shared Services, LLC
CRANBURY, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- MJH Life Sciences®, a premier provider of health care events, media, and education, today announced the acquisition of the Revolutionizing Atopic...
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
November 15, 2024 00:59 ET
|
Regeneron Pharmaceuticals, Inc.
Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by...
Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
November 14, 2024 16:10 ET
|
Fortress Biotech, Inc.
Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults Cosibelimab PDUFA goal date of December 28 for potential approval to treat metastatic or locally...
Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
November 12, 2024 16:01 ET
|
Journey Medical Corporation
U.S. FDA approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of inflammatory lesions of rosacea in adults; launch expected in late Q1 or early Q2 of 2025 ...
Elected Dermatologic Surgeons Commenced Leadership Terms at 2024 ASDS Annual Meeting in Orlando, Florida
November 12, 2024 14:04 ET
|
American Society for Dermatologic Surgery
Schaumburg, Ill., Nov. 12, 2024 (GLOBE NEWSWIRE) -- The American Society for Dermatologic Surgery (ASDS) is pleased to announce the results of its 2024 election. This year, ASDS members voted for...
ASDS Announces 2024 Annual Award Recipients
November 12, 2024 12:16 ET
|
American Society for Dermatologic Surgery
Schaumburg, Ill., Nov. 12, 2024 (GLOBE NEWSWIRE) -- The American Society for Dermatologic Surgery (ASDS) is delighted to announce the 2024 recipients of its annual awards, who were recognized during...
M. Laurin Council, MD, MBA, Takes Office as ASDS/A President
November 12, 2024 11:00 ET
|
American Society for Dermatologic Surgery
Schaumburg, IL, Nov. 12, 2024 (GLOBE NEWSWIRE) -- The American Society for Dermatologic Surgery (ASDS) is pleased to announce that M. Laurin Council, MD, MBA, has assumed her role as President for...
Peptide Therapeutics Market Size to Surpass USD 76.11 Billion by 2033 | Straits Research
November 11, 2024 10:10 ET
|
Straits Research Private Limited - Garner Insights
New York, United States, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Researchers have used peptides to deliver drugs to target cells due to their remarkable efficacy and selectivity towards the different...